Search
for
Sort by
Research 541–570 of 1000+
- Eyebrow Transplantation: A Simplified Technique
- The evolving landscape of eyebrow reconstruction: from traditional flaps to minimally invasive techniques and regenerative medicine
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- PCR108 QUALITATIVE AND PSYCHOMETRIC EVALUATION OF THE CLINRO MEASURE FOR EYEBROW HAIR LOSS AND CLINRO MEASURE FOR EYELASH HAIR LOSS IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA
- Objective quantification of chemotherapy-induced madarosis: a pilot study of an automated computer vision pipeline for eyebrow density assessment
- Low-Dose Oral Minoxidil Improves Hairline and Eyebrow Coverage in Frontal Fibrosing Alopecia: A Prospective Study
- Chemotherapy-Induced Eyebrow Alopecia and Psychological Recovery: Permanent Micropigmentation as a Component of Multidisciplinary Oncological Rehabilitation
- Who Am I? Eyebrow Follicles Minimize Donor-Derived DNA for Germline Testing After Hematopoietic Stem Cell Transplantation
- Comparative evaluation of eyebrow rejuvenation using hibiscus oil 5% (w/v) with and without Gua-sha: A split face randomized control Trial
- Treatment and Prevention of Traumatic Eyebrow Cicatricial Alopecia With Stem Cell Growth Serum
- A Case of Cosmetic-Related Eyebrow Loss: Combined Analysis Using Dermoscopy and Reflectance Confocal Microscopy
- Psychoemotional Outcomes of Permanent Eyebrow Correction in Patients with Alopecia and After Chemotherapy
- Clinical Evaluation of a Mesotherapy Formulation for Weakened and Sparse Eyebrows With Assessment of Some Psychological and Social Aspects
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Cultural Trichotillomania: A Look at Eyebrow Loss in India
- 63532 Impact of Eyebrow and Eyelash Hair Loss on Health-Related Quality of Life Among Patients with Alopecia Areata: Results From a Real-World Survey in 5 European Countries
- Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis
- Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
- Assessment of Clients' Perceptions and Satisfaction With Eyebrow Mesotherapy Treatment
- Assessment and Validity of Trichoscopy for Eyebrow Involvement in Lichen Planopilaris: A Case-Control Study
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib
- Bimatoprost Can Increase Growth and Density of Eyebrow Hair: A Prospective Study on a Group of Young Women
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- A comprehensive evaluation of safety and awareness in eyebrow microblading: a cross-sectional study
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
- 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study